Experienced in Undifferentiated Connective Tissue Disease (UCTD)

Dr. Bryan J. Wolf

Rheumatology
6165 Ridgeview Ct, Ste C, 
Reno, NV 
Accepting New Patients
Experienced in Undifferentiated Connective Tissue Disease (UCTD)
6165 Ridgeview Ct, Ste C, 
Reno, NV 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Bryan Wolf is a Rheumatologist in Reno, Nevada. Dr. Wolf is rated as an Experienced provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). His top areas of expertise are Rheumatoid Arthritis (RA), Polymyalgia Rheumatica, Rhizomelic Pseudopolyarthritis, and Relapsing Polychondritis. Dr. Wolf is currently accepting new patients.

His clinical research consists of participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in NV
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

6165 Ridgeview Ct, Ste C, Reno, NV 89519

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 17, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 6 Less Clinical Trials
Similar Doctors
Distinguished in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Susan L. Knowles
Rheumatology
Distinguished in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Susan L. Knowles
Rheumatology

Carson Valley Medical Center Rural Health Clinic

897 Ironwood Dr, 
Minden, NV 
 (35.2 miles away)
775-782-1610
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Susan Knowles is a Rheumatologist in Minden, Nevada. Dr. Knowles is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). Her top areas of expertise are Rheumatoid Arthritis (RA), Sjogren Syndrome, Psoriatic Arthritis, and Undifferentiated Connective Tissue Disease (UCTD). Dr. Knowles is currently accepting new patients.

Advanced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Ratinder J. Kaur
Rheumatology
Advanced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Ratinder J. Kaur
Rheumatology

Bachman And Scully, Ltd.

160 Country Estates Circle, Suite 2, 
Reno, NV 
 (1.8 miles away)
775-322-9100
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Ratinder Kaur is a Rheumatologist in Reno, Nevada. Dr. Kaur is rated as an Advanced provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). Her top areas of expertise are Rheumatoid Arthritis (RA), Rhizomelic Pseudopolyarthritis, Polymyalgia Rheumatica, and Undifferentiated Connective Tissue Disease (UCTD). Dr. Kaur is currently accepting new patients.

Advanced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Prahlad A. Reddy
Rheumatology
Advanced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Prahlad A. Reddy
Rheumatology

Bachman And Scully, Ltd.

160 Country Estates Circle, Suite 2, 
Reno, NV 
 (1.8 miles away)
775-322-9100
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Prahlad Reddy is a Rheumatologist in Reno, Nevada. Dr. Reddy is rated as an Advanced provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). His top areas of expertise are Rheumatoid Arthritis (RA), Reactive Arthritis, Rhizomelic Pseudopolyarthritis, and Polymyalgia Rheumatica. Dr. Reddy is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wolf's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile